Article
HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.
Oncogene - 27 Oct 2016
Chen C-H, Chang W-H, Su K-Y, Ku W-H, Chang G-C, Hong Q-S, Hsiao Y-J, Chen H-C, Chen H-Y, Wu R, Yang P-C, Chen J J W, Yu S-L
Abstract excerpt
HLJ1 (DNAJB4), a DNAJ/Hsp40 chaperone, has emerged as a novel prognostic marker in lung cancers; however, the molecular contribution and functionality in neoplastic diseases remain to be established. This study demonstrated that HLJ1 inhibits epithelial-mesenchymal transition in vitro and reduces lung cancer metastasis in vivo. Using shRNA silencing and ectopic expression of HLJ1, we found that HLJ1 not only...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.